Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 19:20:1985-1993.
doi: 10.2147/NDT.S484717. eCollection 2024.

Health-Care Utilisation and Costs of Transition from Paliperidone Palmitate 1-Monthly to 3-Monthly Treatment for Schizophrenia: A Real-World, Retrospective, 24-Month Mirror-Image Study

Bo-Chieh Chang  1 , Meng-Hsuan Kuo  1 , Chi-Hui Lee  1 , Ya-Lan Chu  1 , Kuang-Peng Chen  2 , Chun-Liong Tung  2 , Ya-Hui Yang  3 , Chuan-Sheng Hung  4 , Jui-Hsiu Tsai  2   5 , Hung-Yi Chuang  6
Affiliations

Health-Care Utilisation and Costs of Transition from Paliperidone Palmitate 1-Monthly to 3-Monthly Treatment for Schizophrenia: A Real-World, Retrospective, 24-Month Mirror-Image Study

Bo-Chieh Chang et al. Neuropsychiatr Dis Treat. .

Abstract

Introduction: Poor adherence to antipsychotics in patients with schizophrenia is a leading cause of relapse and functional deterioration. Long-acting injectable paliperidone may reduce relapse risks, health-care utilisation, and health-care costs in these patients.

Methods: In this 24-month mirror-image study, we compared health-care utilization and costs before and after the initiation of paliperidone palmitate 3-monthly (PP3M) treatment in patients with schizophrenia spectrum disorders. Before the initiation of PP3M, the patients received paliperidone 1-monthly (PP1M) treatment. The primary study outcomes were changes in health-care utilisation and costs over the study period.

Results: This study included 34 patients with schizophrenia spectrum disorders. During the 12-months period after the initiation of PP3M treatment, the mean duration of hospitalisation decreased from 57.7 to 28.5 days (p = 0.03). Moreover, significant reductions were noted in emergency room visits (PP1M vs PP3M: 0.3 vs 0.0, respectively; p = 0.05) and health-care costs (PP1M vs PP3M: 107,328.8 vs 57,848.6, respectively; p = 0.03).

Conclusion: PP3M may significantly reduce hospitalisation duration, emergency room visits, and health-care costs in patients with schizophrenia.

Keywords: health-care cost; health-care utilisation; long-acting injectable antipsychotics; paliperidone palmitate; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest related to the current work.

References

    1. Freedman R. Schizophrenia. N Engl J Med. 2003;349(18):1738–1749. doi:10.1056/NEJMra035458 - DOI - PubMed
    1. Solmi M, Seitidis G, Mavridis D, et al. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the global burden of disease (GBD) 2019. Mol Psychiatry. 2023;28(12):5319–5327. doi:10.1038/s41380-023-02138-4 - DOI - PubMed
    1. GBD 2019. Mental disorders collaborators. global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137–150. doi:10.1016/S2215-0366(21)00395-3. - DOI - PMC - PubMed
    1. Hong J, Windmeijer F, Novick D, Haro JM, Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (schizophrenia outpatient health outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(5):835–841. doi:10.1016/j.pnpbp.2009.03.034 - DOI - PubMed
    1. Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2. doi:10.1186/1471-244X-10-2 - DOI - PMC - PubMed

LinkOut - more resources